Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain
定义和表征脑中播散性肿瘤细胞休眠的微环境驱动因素
基本信息
- 批准号:10158461
- 负责人:
- 金额:$ 32.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-05 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAgonistAgrinAstrocytesAutopsyBasement membraneBindingBlood VesselsBone MarrowBrainBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineBreast cancer metastasisCancer PatientCell ProliferationClinicalClinical DataCuesDataDepositionDevelopmentDystroglycanEarly DiagnosisEnzymesGoalsHumanIndividualInvestigationLamininLesionLiverLungMalignant NeoplasmsMeasuresMediatingMetastatic breast cancerMetastatic malignant neoplasm to brainMutationNeoplasm MetastasisOrganOutcome MeasurePathway interactionsPatientsPenetrancePhasePublishingRecording of previous eventsResourcesSeedsSeminalSignal TransductionSignaling MoleculeSiteSoilSpecimenSuppressor-Effector T-LymphocytesSystemic TherapyTestingTherapeuticTimeTransgenic MiceTransgenic ModelUrsidae FamilyWomanWorkXenograft Modelbaseboneglycosylationhigh dimensionalityin vivoinnovationintravital imagingknock-downmalignant breast neoplasmmetastasis preventionmouse modelmutantneoplastic cellpreventprophylacticreceptor
项目摘要
Project Summary
Brain metastases arise later than metastases at other sites. Once they do, they are rapidly debilitating and
lethal. The time it takes for brain metastases to emerge suggests that a dormancy phase is involved. This
notion is supported by clinical and experimental data. Indeed, our own preliminary data show that breast
cancer cells become dormant upon entering the brain, and that emerging from this state is the rate-limiting step
of metastasis. These data indicate that targeting dormant disseminated tumor cells (DTCs) is a logical
approach to brain metastasis prevention. However, despite a growing understanding of dormancy mechanisms
in common metastatic sites like lung and bone marrow, a parallel understanding of how DTCs are driven into a
dormant state in brain has not developed. The overarching goal of this proposal is to address this issue. We
will formulate a basic framework for how the brain microenvironment drives DTCs into a dormant state, with
support from clinical specimens, so that we can leverage this understanding for therapies that keep DTCs
dormant indefinitely.
Our recent investigations have revealed that dormant DTCs occupy the brain’s vascular niche, where
perivascular astrocytes suppress their outgrowth. We suspect that astrocytic contributions to the parenchymal
basement membrane are responsible for DTC suppression, and that these contributions converge on a
common receptor: dystroglycan. Therefore, our hypotheses are that: (i) astrocytic basement membrane is a
key driver of DTC dormancy, and (ii) dystroglycan function must remain intact for DTCs to interpret these
signals. We will test these hypotheses through two specific aims:
Aim 1. Determine whether astrocytic basement membrane promotes and sustains DTC dormancy.
Aim 2. Elucidate the dystroglycan-mediated signaling axis that effects DTC quiescence in brain.
We have brought every relevant resource to bear in order to address these aims. These resources span: (i)
long-term intravital imaging to determine the fate of DTCs following ablation of DTC-associated astrocytes; (ii)
transgenic mice to measure the outcome of ablating astrocyte derived basement membrane molecules on DTC
fate; (iii) rare clinical specimens to establish whether astrocytes and astrocytic basement membrane are asso-
ciated with dormant DTCs in humans; and (iv) a host of mutant, over- and under- expression constructs to
solve how dystroglycan functions from the outside-in to drive DTC quiescence.
The significance and innovation of this work lie in the identification of the first dormancy drivers in brain,
ultimately to unravel dystroglycan-driven signaling that effects disseminated breast tumor cell quiescence. This
work will set the stage for agonists of dystroglycan function that serve as prophylactics for brain metastasis
prevention.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cyrus M Ghajar其他文献
Cyrus M Ghajar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cyrus M Ghajar', 18)}}的其他基金
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance
化疗驱动的血管分泌组进化及其在治疗抵抗中的作用
- 批准号:
10321289 - 财政年份:2021
- 资助金额:
$ 32.33万 - 项目类别:
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance
化疗驱动的血管分泌组进化及其在治疗抵抗中的作用
- 批准号:
10601470 - 财政年份:2021
- 资助金额:
$ 32.33万 - 项目类别:
Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance
化疗驱动的血管分泌组进化及其在治疗抵抗中的作用
- 批准号:
10544717 - 财政年份:2021
- 资助金额:
$ 32.33万 - 项目类别:
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain
定义和表征脑中播散性肿瘤细胞休眠的微环境驱动因素
- 批准号:
10400671 - 财政年份:2020
- 资助金额:
$ 32.33万 - 项目类别:
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain
定义和表征脑中播散性肿瘤细胞休眠的微环境驱动因素
- 批准号:
10685943 - 财政年份:2020
- 资助金额:
$ 32.33万 - 项目类别:
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain
定义和表征脑中播散性肿瘤细胞休眠的微环境驱动因素
- 批准号:
10601281 - 财政年份:2020
- 资助金额:
$ 32.33万 - 项目类别:
Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain
定义和表征脑中播散性肿瘤细胞休眠的微环境驱动因素
- 批准号:
10037395 - 财政年份:2020
- 资助金额:
$ 32.33万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.33万 - 项目类别:
Research Grant